Trending Market News

Shell has agreed to acquire Canadian energy company ARC Resources in a deal valued at $16.4 billion, including debt. The acquisition was announced on April 27 and represents a significant expansion of Shell's operations in the Canadian energy sector.

• The total deal value is $16.4 billion, which includes the assumption of ARC Resources' debt obligations
• ARC Resources is a Canadian energy company being acquired by Shell, the major oil and gas multinational
• This acquisition marks a major consolidation move in the energy sector as Shell expands its North American portfolio

Medical device maker Medtronic confirmed on April 27 that a cyberattack on its corporate IT systems last week did not impact its products, patient safety, manufacturing, or distribution operations. The company stated the incident is not expected to materially affect its business or financial results, though it highlights growing cybersecurity risks facing the medical device industry.

• Medtronic's IT network remains separate from systems supporting products, manufacturing, and distribution, preventing operational disruption despite the attack
• The incident follows a destructive cyberattack on competitor Stryker that delayed surgeries and disrupted order processing, product manufacturing, and shipping capabilities
• Medtronic has activated response plans and engaged cybersecurity experts to contain the attack, though the company did not disclose the attackers' identity or specific attack details

United Airlines CEO Scott Kirby confirmed that he approached American Airlines about a potential merger between the two major U.S. carriers. The confirmation marks a significant development in the airline industry, as a combination of United and American would create one of the world's largest airlines.

• United CEO Scott Kirby publicly acknowledged initiating merger discussions with American Airlines
• The potential consolidation would involve two of the largest U.S. carriers, significantly reshaping the domestic airline landscape
• This is a developing story with limited details currently available about the scope or status of merger discussions

Verizon raised its annual profit forecast after adding 55,000 monthly bill-paying wireless subscribers in Q1, exceeding analyst expectations for a loss of 8,000 subscribers. The surprise gain was driven by revamped customer offers and bundled plans that helped the company reclaim market share from rivals AT&T and T-Mobile.

• Verizon now expects 2026 adjusted profit between $4.95-$4.99 per share and forecasts full-year postpaid phone net additions in the upper half of its 750,000 to 1 million target range
• Q1 revenue of $34.4 billion missed estimates of $34.84 billion, partly due to $20 customer credits issued after a 10-hour January service outage
• The company's strategy of offering discounted bundles combining high-speed internet and wireless plans aims to boost customer retention, with results including contributions from the recently acquired Frontier

Intellia Therapeutics announced its Crispr-based treatment for hereditary angioedema succeeded in a Phase 3 trial, marking a significant milestone for in vivo gene editing. The one-time infusion reduced swelling attacks by 87% compared to placebo, with 62% of patients attack-free after six months. The company has begun FDA submission and plans a 2027 U.S. launch if approved.

• The treatment uses Crispr to edit DNA directly in the liver (in vivo), differentiating it from Vertex's FDA-approved ex vivo approach that edits cells outside the body
• Safety profile described as 'favorable' with common side effects including infusion reactions, headaches, and fatigue, though analysts monitored closely after a patient death in a separate Intellia trial
• If approved, lonvoguran ziclumeran will compete with about a dozen chronic HAE drugs, facing commercial uncertainty typical of one-time genetic therapies despite no observed waning of effects in nearly six years of data

Eli Lilly announced it will acquire Ajax Therapeutics, a private blood cancer treatment developer, for up to $2.3 billion in cash. The deal centers on Ajax's lead experimental drug AJ1-11095, an oral treatment for myelofibrosis currently in early-stage testing. The acquisition includes an upfront payment plus milestone-based payments tied to clinical and regulatory achievements.

• Ajax's lead asset AJ1-11095 is a once-daily oral treatment in early-stage testing for previously treated myelofibrosis patients, a rare chronic blood cancer affecting bone marrow
• Clinical proof-of-concept data is expected in 2026, after which Lilly plans to advance the drug into registrational trials
• The $2.3 billion deal structure includes upfront cash and contingent payments based on achieving specific clinical and regulatory milestones

Domino's Pizza missed first-quarter same-store sales estimates as budget-conscious Americans reduced discretionary spending amid high inflation and economic uncertainty. U.S. same-store sales grew only 0.9%, the slowest pace in three quarters, while international sales declined 0.4% versus expectations of a 0.7% rise. The company announced a $1 billion share buyback and revived promotional offers to attract value-focused customers.

• U.S. same-store sales increased just 0.9% in Q1, below estimates, marking the slowest growth in three quarters as consumers cut back on dining out
• International same-store sales fell 0.4% compared to analyst expectations of a 0.7% increase, with pressure from franchisees in markets like Australia
• Domino's relaunched its $9.99 'Best Deal Ever' promotion and introduced new menu items like Parmesan-stuffed crust pizza to compete for price-sensitive customers

CATL, the world's largest electric vehicle battery manufacturer, has launched a $5 billion share offering in Hong Kong through an accelerated bookbuild of new H-shares. The Chinese battery giant plans to use the proceeds for global capacity expansion, zero-carbon business development, R&D, and general working capital.

• The offering represents a significant capital raise through primary H-shares listed in Hong Kong
• Proceeds will fund global capacity expansion and development of the company's zero-carbon business footprint
• The raise comes as CATL maintains its position as the world's largest battery manufacturer amid growing EV demand

Google will establish its first-ever AI campus in Seoul, South Korea, following a meeting between South Korean President Lee Jae Myung and Google DeepMind CEO Demis Hassabis on April 27. The campus aims to foster collaboration between Google engineers and local Korean startups and tech talent, with a memorandum of understanding signed between the Science Ministry and Google.

• South Korea requested Google send at least 10 engineers from U.S. headquarters to staff the campus, which will be Google's first AI campus globally
• DeepMind plans to deepen partnerships with major Korean companies including Samsung, SK Hynix, Hyundai's Boston Dynamics, and LG for new joint AI projects
• President Lee raised concerns about AI-related job losses and the potential need for a base wage, while Hassabis emphasized training the next generation through internships and programs at the AI hub

Adidas shares surged after Kenya's Sabastian Sawe became the first person to run a sub-two-hour marathon in an official race at the London Marathon while wearing Adidas' Adizero Adios Pro Evo 3 trainers. The top three finishers, including Ethiopia's Yomif Kejelcha and record-breaking Tigst Assefa, all wore the same Adidas shoe model. This achievement represents a major marketing victory for Adidas over rival Nike in the competitive running shoe market.

• Sawe set a new world record time of 1:59:30 at the London Marathon wearing Adidas' flagship 'supershoe'
• The Adizero Adios Pro Evo 3 trainers will launch exclusively via the Adidas app on Thursday at $500 per pair
• All three podium finishers wore the same Adidas model, delivering significant brand validation ahead of the product launch

SK Hynix shares surged over 7% to a record high on Monday, outperforming rival Samsung Electronics which rose only 2.5%. The rally was driven by renewed artificial intelligence demand expectations following strong earnings results from U.S. chipmaker Intel.

• SK Hynix's stock hit an all-time high with a 7% gain, significantly outpacing Samsung's 2.5% increase
• The performance gap was partly attributed to Samsung facing labor challenges from unionized workers planning a strike in South Korea in May
• Intel's positive earnings results rekindled investor optimism about AI chip demand, benefiting memory chip makers like SK Hynix

Sun Pharmaceutical Industries announced it will acquire U.S. drugmaker Organon & Co in an all-cash transaction valued at approximately $11.75 billion. The deal was announced jointly by both companies on Sunday, April 26. This represents a major consolidation move in the pharmaceutical industry by India's Sun Pharma.

• The acquisition is structured as an all-cash deal, indicating Sun Pharma will pay the full $11.75 billion purchase price without stock considerations
• Organon is a U.S.-based drugmaker being acquired by India's Sun Pharmaceutical Industries
• The transaction represents one of the larger pharmaceutical M&A deals, with an $11.75 billion valuation for Organon

The U.S. Supreme Court hears arguments Monday in Bayer's case seeking to limit Roundup cancer lawsuits, with a ruling expected by end of June. Bayer faces claims from approximately 65,000 plaintiffs alleging the weedkiller causes non-Hodgkin lymphoma, while the company has reached a $7.25 billion settlement awaiting final court approval. The case centers on whether federal pesticide labeling law preempts state-level failure-to-warn claims.

• Bayer argues EPA's finding of no cancer risk preempts state law claims for failure to warn; a ruling in its favor would eliminate failure-to-warn claims but not negligence or misrepresentation claims in existing lawsuits
• The company reached a $7.25 billion settlement in February to resolve most current and potential future lawsuits, with final approval hearing scheduled for July
• Plaintiffs must decide by June 4 whether to opt out of the settlement and continue litigation, potentially before the Supreme Court issues its ruling

German biotech company CureVac sued Moderna in Delaware federal court on April 24, alleging that Moderna's COVID-19 vaccine Spikevax infringes eight CureVac patents related to messenger RNA technology. CureVac claims Moderna copied its technology for stabilizing fragile mRNA and is seeking royalties from Spikevax sales. This lawsuit is part of a broader wave of patent litigation among biotech companies over lucrative COVID-19 vaccine technologies.

• CureVac alleges Moderna infringed eight U.S. patents by copying its mRNA stabilization technology for use in the Spikevax vaccine
• BioNTech, which partnered with Pfizer on competing vaccine Comirnaty, also sued Moderna in February over its next-generation mNEXSPIKE shot
• Multiple biotech companies are pursuing patent royalties from COVID-19 vaccine makers, with Moderna itself having sued Pfizer and BioNTech over Comirnaty in 2022

Johnson & Johnson will begin marketing four medications on the Trump administration's TrumpRx website starting Friday, according to CBS News. The move follows a January agreement where J&J voluntarily agreed to reduce drug prices and expand Medicaid access in exchange for exemption from administration tariffs. The specific drugs to be featured have not been verified.

• J&J reached a voluntary agreement with the Trump administration in January to reduce drug prices for Americans and expand affordable prescription access under Medicaid
• In exchange for these commitments and marketing products on TrumpRx, the healthcare conglomerate received an exemption from administration tariffs
• The specific four medications slated for the TrumpRx platform have not been confirmed, and J&J did not immediately respond to requests for comment

IHeartMedia Inc is in preliminary merger discussions with Sirius XM Holdings, according to Bloomberg News citing sources familiar with the talks. The discussions remain in early stages with no guarantee a deal will materialize. Neither company has provided official comment on the reported negotiations.

• The talks between the two major radio and audio entertainment companies are preliminary in nature
• No guarantee exists that negotiations will result in a final merger agreement
• Both IHeartMedia and Sirius XM declined to comment on the merger reports when contacted by Reuters

The Trump administration imposed sanctions on Chinese refinery Hengli Petrochemical and approximately 40 shipping companies and vessels for purchasing billions of dollars worth of Iranian oil. The sanctions aim to restrict Iran's oil exports, though experts note that targeting Chinese banks facilitating these transactions would be more effective than sanctioning independent refineries with limited U.S. financial system exposure.

• Hengli Petrochemical is one of Iran's largest crude oil customers; China purchases over 80% of Iran's shipped oil according to 2025 Kpler data
• Independent 'teapot' refineries account for roughly a quarter of Chinese refinery capacity and are somewhat immune to U.S. sanctions due to minimal exposure to the U.S. financial system
• Iranian oil now trades at premiums to Brent prices as teapot refiners face increased competition after the U.S. issued temporary sanctions waivers that could allow India to purchase more Iranian crude

The U.S. Space Force awarded contracts worth up to $3.2 billion to 12 companies, including SpaceX, Northrop Grumman, Lockheed Martin, and Anduril, to develop space-based missile defense interceptors as part of President Trump's Golden Dome initiative. The program represents a significant shift from ground-based systems to orbital weapons capable of engaging missile threats earlier in their flight path, with demonstration capability targeted for 2028.

• Twenty agreements were awarded in late 2025 and early 2026 with a combined potential value of $3.2 billion to develop Space-Based Interceptor (SBI) systems that can neutralize threats from orbit
• The Golden Dome architecture will integrate space-based interceptors with sensors and command-and-control systems, including advanced satellite networks and orbital weaponry
• The program aims to demonstrate integrated capability within the Golden Dome architecture by 2028, with competing prototypes setting up a competition for future contracts worth tens of billions of dollars

Google-parent Alphabet is investing $10 billion in AI startup Anthropic at a $350 billion valuation, with up to $30 billion more contingent on performance targets, according to Bloomberg News. This follows Amazon's recent $5 billion investment in the same company, highlighting intense competition among tech giants to secure stakes in leading AI developers.

• Google is committing $10 billion immediately in cash, with potential for an additional $30 billion if Anthropic meets performance milestones
• The deal values Anthropic at $350 billion, reflecting the premium tech giants are paying for AI capabilities
• Amazon recently invested $5 billion in Anthropic with up to $20 billion more possible, showing multiple major players competing for the Claude AI creator

Eli Lilly's newly launched oral weight loss drug Foundayo recorded 3,707 prescriptions in its second week on the U.S. market, representing slower uptake compared to competitor Novo Nordisk's oral Wegovy, which had 18,410 prescriptions in its second week. The launch is being closely watched as a test of whether Lilly can compete with Novo Nordisk's first-mover advantage in the oral obesity drug market.

• Foundayo had 1,390 prescriptions in its first week and 3,707 in its second week, compared to Novo's oral Wegovy which had 3,071 first-week prescriptions and 18,410 in its second week
• Analysts at RBC Capital Markets said the uptake is 'likely to be received negatively,' while J.P. Morgan noted the slower ramp is unsurprising given Wegovy's time-to-market and brand recognition advantages
• Lilly cautioned that early weekly figures may not capture the full breadth of pharmacy partners and should be 'best interpreted over time rather than as a complete count'